Anti-tumor necrosis factor (TNF)-α therapy in undifferentiated spondyloarthropathy

Clinical and Experimental Rheumatology

Volumn 20, Issue 6 SUPPL. 28, 2002, Pages

  Scnarr, S ^a   Kuipers, J G ^a   Zeidler, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adalimumab; Etanercept; Infliximab; Tumour necrosis factor; Undifferentiated spondyloarthropathy

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BIOLOGICAL RESPONSE MODIFIER; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; HEART PALPITATION; HUMAN; INFLAMMATION; NEUROTOXICITY; PHYSIOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPINE DISEASE; SPONDYLOARTHROPATHY; STAGING; DRUG ANTAGONISM; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17144445219     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. MOLL JM, HASLOCK I, MACRAE IF, WRIGHT V: Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behçet's syndrome. Medicine (Baltimore) 1974; 53: 343-64.
2. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
3. AMOR B, DOUGADOS M, MIJIYAWA M: Criteria of the classification of spondylarthropathies. Rev Rhum 1990; 57: 85-9.
4. DOUGADOS M, VAN DER LINDEN S, JUHLIN R et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
5. ZEIDLER H, MAU W, KHAN MA: Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am 1992; 18: 187-202.
6. El GABALAWY HS, GOLDBACH-MANSKY R, SMITH D et al.: Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis Rheum 1999; 42: 1696-705.
7. MAU W, ZEIDLER H, MAU R et al.: Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow-up. J Rheumatol 1988; 15: 1109-14.
8. SAMPAIO-BARROS PD, BERTOLO MB, KRAEMER MH, MARQUES-NETO JF, SAMARA AM: Undifferentiated spondyloarthropathies: A 2-year follow-up study. Clin Rheumatol 2001; 20: 201-6.
9. KOEHLER L, KUIPERS JG, ZEIDLER H: Managing seronegative spondarthrifides. Rheumatology (Oxford) 2000; 39: 360-8.
10. DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618-27.
11. BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
12. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
13. VAN DEN BOSCH F, KRUITHOF E, BAETEN D, De KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study. Ann Rheum Dis 2000; 59: 428-33.
14. KRUITHOF E, VAN DEN BF, BAETEN D, De KEYSER F, MIELANTS H, VEYS EM: TNF-alpha blockade with infliximab in patients with active spondyloarthropathy: follow up of one year maintenance regimen. Arthritis Rheum 2001; 44 (Suppl.): S90 (Abstract).
15. BAETEN D, KRUITHOF E, VAN DEN BF et al.: Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001; 44: 186-95.
16. MARZO-ORTEGA H, MCGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112-7.
17. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
18. CALIN A, GARRETT S, WHITELOCK H et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
19. BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab. J Rheumatol 2002; 29: 118-22.
20. VAN DEN BOSCH F, KRUITHOF E, BAETEN D et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-65.
21. DOUGADOS M, GUEGUEN A, NAKACHE JP, NGUYEN M, MERY C, AMOR B: Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988; 15: 302-7.